Development

Webinar Date/Time: Tue, Nov 18, 2025 11:00 AM EST

Non-parenteral alternatives for biologics remain a clinical imperative and a formidable challenge.

CHMP’s positive opinion for a subcutaneous form of anifrolumab paves the way for a once-weekly at-home lupus treatment option in Europe.

Michael Ritchie, chief commercial officer at Champions Oncology, explains what makes radiopharmaceuticals unique in the treatment of cancer.

This quiz measures your comprehension of one of our recent feature articles.

This quiz measures your comprehension of one of our recent feature articles.

ARM board member Miguel Forte highlights education programs, innovation hubs, and hands-on training to foster workforce expertise in the biopharma industry.

Maximizing value in advanced therapies requires the use of proven approaches, expert logistics, and tailored distribution, says Miguel Forte, board member of ARM.

Groundbreaking gene delivery, scalable IPSC approaches, and advanced production solutions will impact future CGT development, according to ARM board member, Miguel Forte.

ARM Board Member Miguel Forte highlights CGT investment shifts, sector resilience, and alternative funding strategies during Meeting on the Mesa.

Each step of development and manufacturing is becoming more interconnected, and BioPharm's September/October issue highlights the strategies, tools, and innovations shaping the future of the field.

Webinar Date/Time: Wed, Nov 5, 2025 11:00 AM EST

US President Donald Trump confirmed AstraZeneca as the second of 17 major pharmaceutical companies, after Pfizer, to agree to most-favored-nation pricing protocols.

Industry leaders at Meeting on the Mesa discussed big biopharma’s role in next-step CGT scale, focusing on manufacturing quality and patient access.

To increase CAR-T patient access, healthcare professionals must standardize high-quality delivery, shift to outpatient settings, and overcome current logistical barriers, industry leaders said at a session during the Cell and Gene Meeting on the Mesa.

In a session at the Cell and Gene Meeting on the Mesa, Prime Medicine CEO Allan Reine discussed how prime editing offers versatile, safe gene correction, but that delivery to target cells remains a major hurdle.

A growing demand for liquid medicines is driven by patient groups' unique needs, improving compliance through flexible and palatable dosing options.

By licensing Talicia to priority markets, RedHill targets growing antibiotic resistance to the cancer-associated H. pylori bacteria with an FDA-approved, fixed-dose therapy

The regulatory progress for AAVantgarde’s AAVB-039 underscores advances in dual-vector gene therapy, as well as scalable manufacturing and efficient rare-disease clinical development.

The study by Integra Therapeutics and partners reveals how AI-engineered proteins could expand gene-editing tools and streamline development of advanced therapies.

On July 31, President Donald Trump said the federal government would “deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices” should companies fail to comply.

This innovative trial guidance accelerates cell and gene therapy development for rare diseases, boosting biopharma efficiency and data maximization.

Webinar Date/Time: Wed, Oct 22, 2025 11:00 AM EDT

Novartis expands its immunology pipeline with the Tourmaline acquisition and tests direct-to-patient model to reshape drug manufacturing strategies.